右侧头臂静脉入路植入静脉输液港临床应用

目的 探讨右侧头臂静脉入路行完全植入式静脉输液港(TIVAP)植入的可行性及安全性.方法 回顾性分析2013年3月至2015年12月采用BCV入路植入TIVAP共493例患者临床资料,其中男137例,女356例;年龄29～78岁,平均(47.3±13.2)岁.总结穿刺成功率及留置过程相关并发症.结果 手术成功率为100％,首次穿刺成功率为99％ (488/493).手术时间18～35 min,平均(22.5±8.3) min.术中误穿动脉3例(0.61％,3/493),未见血胸、气胸等严重并发症.术后患者携TIVAP时间为124～986 d,平均(271.1±53.8)d;并发症发生率为2.25％(11/488),包括港穴出血2例,导管相关感染1例,部分血栓形成2例,纤维蛋白鞘形成6例,未见导管异位、断裂、置管相关夹闭综合征(POS)等严重并发症.结论 经右侧BCV入路行TIVAP植入,穿刺成功率高,安全可靠,可为临床植入TIVAP提供另一入路选择.

The placement of totally implantable venous access port via right brachiocephalic vein access: its clinical application

Objective To evaluate the feasibility and safety of embedding the totally implantable venous access port (TIVAP) via the access of right brachiocephalic vein (BCV).Methods The clinical data of 493 patients,who underwent the placement of TIVAP by using right BCV route during the period from March 2013 to December 2015,were retrospectively analyzed.The patients included 137 males and 356 females,with a mean age of (47.3±13.2) years old (ranging from 29 to 78 years old).The puncture success rate and TIVAP indwelling procedure-related complications were analyzed.Results The technical success rate was 100％,the success rate of initial puncturing was 99％ (488/493).The mean operation time was (22.5± 8.3) minutes (range of 18-35 minutes).Mis-puncturing of artery happened in 3 patients (0.61％,3/493);and no severe complications such as hemothorax or pneumothorax occurred.After implantation,the patients carried TIVAP for 124-986 days,with a mean of (271.1±53.8) days.The incidence of complications was 2.25％ (11/488),including hemorrhage at port site (n=2),catheter-related infection (n=l),partial thrombosis (n=2),and formation of fibrous protein sheath (n=6).No serious complications such as displacement or rupture of catheter,or catheter pinch-off syndrome (POS),etc.were observed.Conclusion The implantation of TIVAP by using right BCV route has high puncturing success rate,the technique is safe and reliable,and it can provide another option of catheter access for the clinical performance of TIVAP implantation.